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Normal tissue damage limits the efﬁcacy of anticancer therapy. For anthracyclines, the clinically most relevant adverse effect is
cardiotoxicity. The mechanisms involved are poorly understood and putative cardioprotectants are controversially discussed.
Here, we show that the lipid-lowering drug lovastatin protects rat H9c2 cardiomyoblasts from doxorubicin in vitro. Protection by
lovastatin is related to inhibition of the Ras-homologous GTPase Rac1. It rests on a reduced formation of DNA double-strand
breaks, resulting from the inhibition of topoisomerase II by doxorubicin. Doxorubicin transport and reactive oxygen species are
not involved. Protection by lovastatin was conﬁrmed in vivo. In mice, lovastatin mitigated acute doxorubicin-induced heart
and liver damage as indicated by reduced mRNA levels of the pro-ﬁbrotic cytokine connective tissue growth factor (CTGF) and
pro-inﬂammatory cytokines, respectively. Lovastatin also protected from doxorubicin-provoked subacute cardiac damage as
shown by lowered mRNA levels of CTGF and atrial natriuretic peptide. Increase in the serum concentration of troponin I and
cardiac ﬁbrosis following doxorubicin treatment were also reduced by lovastatin. Whereas protecting the heart from harmful
doxorubicin effects, lovastatin augmented its anticancer efﬁcacy in a mouse xenograft model with human sarcoma cells. These
data show that statins lower the incidence of cardiac tissue injury after anthracycline treatment in a Rac1-dependent manner,
without impairing the therapeutic efﬁcacy.
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Anthracyclinederivativessuchasdoxorubicinrankamongthe
most potent antineoplastic drugs.
1 However, an unresolved
problem associated with their use is normal tissue damage,
in particular their dose-dependent acute and delayed cardio-
toxicity, which manifests as congestive heart failure due to
cardiomyopathy in upto 20% of the patients.
2–4 The formation
of reactive oxygen species (ROS), generation of peroxynitrite
by nitric oxide synthases (NOS) and/or inhibition of topo-
isomerase II (topo II) are discussed to be responsible for the
cardiotoxic side effect of doxorubicin.
4–6 Co-administration of
anthracyclines with the antioxidant dexrazoxane as a cardio-
protectant is in dispute because the molecular mechanisms
involved in anthracycline-induced cardiotoxicity, as well as
the molecular effects of dexrazoxane are still unclear.
7–9
Moreover, it is under debate whether dexrazoxane has
negative effects on the antitumor efﬁcacy of anthracyclines.
10,11
Doxorubicin-induced cardiac dysfunction has been related to
the induction of iNOS leading to an increase in highly cytotoxic
peroxynitrite.
12 Yet, pharmacological targeting of iNOS-
mediated NO production as cardioprotective strategy for
anthracycline treatments is controversially discussed. This is
because mitochondrial damage and cardiotoxicity provoked by
doxorubicin were reported to be even enhanced in iNOS
knockouts.
13,14 Furthermore, unselective NOS inhibition by
N-nitro-L-arginine methyl ester increased doxorubicin-induced
mortality in mice.
15 Therefore, the development of alternative
cardioprotective strategies for anthracycline-based anticancer
therapy is of high importance.
16
HMG-CoA reductase inhibitors (statins), whichare clinically
established for lipid-lowering purposes, are known to have
pleiotropic biological effects.
17 These pleiotropic effects
are mainly based on the inhibition of the prenylation of
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17–19 High
doses of statins enhance the tumor cell kill of anticancer
drugs
20,21 by impairing G1–S transition
22 and triggering
apoptosis.
23,24 Furthermore, statins promote TNFa-triggered
apoptosis
25 and reverse chemoresistance by inhibition of
NF-kB.
26 Apart from increasing the antitumor activity of
numerous anticancer drugs in vitro and in vivo,
19 low doses
of statins reduce cell death of primary human endothelial cells
(HUVECs) provoked by doxorubicin and ionizing radiation
in vitro.
27,28 Furthermore, statins protect the intestine from the
sideeffects ofradiotherapyinvivo.
29–31Thesereportspoint to
a dual beneﬁcial function of statins in anticancer therapy, that
is, the promotion of anticancer drug-induced killing of
malignant cells and concomitant protection of normal cells.
Based on these reports and the well-documented cardiopro-
tective function of statins,
32 we hypothesized that statins
might be clinically useful for alleviating adverse effects of
anthracyclines, in particular anthracycline-induced cardiotoxi-
city.Toscrutinizethishypothesis,weinvestigatedtheeffectof
lovastatin on doxorubicin-induced damage to cardiomyocytes
using both in vitro and in vivo model systems. Here, we show
that the HMG-CoA reductase inhibitor lovastatin signiﬁcantly
protects against doxorubicin-induced cardiac toxicity and, at
the same time, augments the anticancer effect of doxorubicin.
Results
Lovastatin reduces doxorubicin-induced cell death
in vitro. To investigate whether statins are able to protect
cardiomyoblasts against doxorubicin-induced cytotoxicity, we
performed in vitro experiments using the well-established
rat H9c2 cardiomyoblast system. Doxorubicin induced a
dose-dependent increase in the frequency of apoptotic cells
(Figure 1a). Lovastatin clearly protected H9c2 cells from
doxorubicin-induced apoptosis (Figure 1a). Measuring
cell viability, the 50% inhibitory concentration (IC50)o f
doxorubicin increased from 1.5 to 5.0mM in the presence
of the statin, conﬁrming the protective effect of lovastatin. To
elucidate the molecular mechanisms involved in the anti-
apoptotic statin effect, the impact of lovastatin on cellular
uptake of doxorubicin (inﬂux) and its removal (efﬂux) was
monitored. Doxorubicin inﬂux and efﬂux were not affected
by lovastatin (Figure 1b). Correspondingly, the mRNA
expression levels of the drug transporters mdr-1 and mrp-1
were not enhanced by the statin (Figure 1c). The anti-
apoptotic statin effect is likely not related to changes in
cell-cycle progression because lovastatin did not impact
the number of cells arrested in G2/M phase after doxorubicin
exposure and, furthermore, did not inﬂuence the level of
Chk-1 phosphorylation stimulated by the anthracycline
(Supplementary Figure S1).
Lovastatin protects from doxorubicin-induced
genotoxicity. Induction of DNA damage, notably DNA
double-strand breaks (DSBs), represents the major
mechanism by which anthracyclines provoke cell death.
33
DNA damage triggers a stress response referred to as the
DNA damage response (DDR).
34 Phosphorylated H2AX
(gH2AX) is a frequently used marker of DNA damage,
35 in
particular DNA DSBs.
36,37 H2AX phosphorylation was
analyzed by western blot analysis and, additionally, by the
detection of gH2AX foci by immunohistochemistry. Western
blot analysis showed that doxorubicin increased the level of
Figure1 Lovastatinprotectsratcardiomyoblastsfromdoxorubicin-inducedcelldeath.H9c2cellswereleftuntreated( Lova)orwerepre-treatedovernightwithlovastatin
(þLova) (20mM) before pulse treatment (1h) with the indicated concentrations of doxorubicin was performed. (a) Incubation was continued for 72h in the presence of
lovastatin (1mM). The percentage of apoptotic cells was analyzed by FACS-based determination of Annexin-V-positive cells. Results presented are the mean±S.E.M. from
four independent experiments. (b) To measure doxorubicin transport, samples were taken for FACS analysis before the pulse treatment (Control), directly after the pulse
(þDoxo (1mM, 1h)) and 6h after pulse treatment. The inherent ﬂuorescence of doxorubicin was used to monitor its uptake. The shift to the right from peak 1 (untreated
control) to peak 2 reﬂects the increase in intracellular ﬂuorescence which is due to doxorubicin uptake. To determine doxorubicin efﬂux, doxorubicin pre-loaded cells were
postincubatedfor6hintheabsenceofthedrug.Thedecreaseincellularﬂuorescenceoccurringduringthistime(thatis,theshiftfrompeak2topeak3)representstheefﬂuxof
doxorubicin. (c) The mRNA level of the major drug transporters mdr-1 and mrp-1 was analyzed before doxorubicin treatment by quantitative real-time RT-PCR analysis.
Results presented are the mean±S.D. from three independent experiments
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Cell Death and DiseasegH2AX. Lovastatin pre-treatment signiﬁcantly attenuated this
response (Figure 2a). Immunohistochemical analysis of
gH2AX foci formation showed similar results (Figure 2b).
The same holds true for assaying the formation of DSBs by
the neutral comet assay (Figure 2c). The number of DNA
single-strand breaks, as monitored by the alkaline comet
assay, was only marginally affected by the statin (Figure 2d).
Based on these data we conclude that lovastatin protects
H9c2 cardiomyoblasts from early DNA damage induction (that
is, formation of DSBs) by doxorubicin. Anthracycline-induced
DSBs are known to mainly result from the inhibition of
topoisomerase II (topo II).
8,38 Therefore it is important to note
that the expression levels of topo IIa and topo IIb protein were
not altered by the statin (Figure 2e). Furthermore, the protein
level of topo II isoforms was not affected by doxorubicin,
neither in the presence nor absence of lovastatin (Figure 2f).
Hence, the geno-protective effect of lovastatin is independent
of changes in topo II protein expression.
Protection by lovastatin is independent of reactive
oxygen species. The formation of ROS and/or inhibition
of topo II are thought to be responsible for the cardiotoxicity
of doxorubicin.
4,5 At the time when H2AX phosphorylation
occurred in our experimental setting, ROS formation was not
detectable (Figures 3a and b). Furthermore, pre-treatment of
H9c2 cardiomyocytes with three different antioxidants
(that is, curcumin, resveratrol and N-acetylcysteine) did
not signiﬁcantly constrain gH2AX formation stimulated by
doxorubicin (Figure 3c). These data indicate that the geno-
protective effect of lovastatin rests on the inhibition
of doxorubicin-mediated effects on topo II rather than an
interference with the formation or detoxiﬁcation of ROS. In
line with this, H2AX phosphorylation provoked by the speciﬁc
topo II inhibitor etoposide, which does not produce ROS, was
also attenuated by lovastatin (Figure 3d). The protective
effect of lovastatin appears to be speciﬁc for topo II poisons
as it does not apply to ionizing radiation (Figure 3e).
Rac1 is involved in the doxorubicin-induced DNA
damage response. Protection from doxorubicin-induced
DNA damage response was also observed upon inhibition
of geranylgeranyltransferase, but not following inhibition
Figure 2 Lovastatin protects H9c2 cells from doxorubicin-induced genotoxicity. Untreated ( Lova) or lovastatin (þLova) (20mM, overnight) pre-treated cells were
exposedto doxorubicin (1mM). (a) H2AX phosphorylation was analyzed 1h after doxorubicin treatment by western blot. The relativegH2AX level in untreated control was set
to 1.0. Signal intensities were quantiﬁed densitrometrically. The histogram shows the mean±S.D. from six independent experiments. *Pr0.05, signiﬁcant difference as
compared with the Doxo-treated cells. (b) The formation of gH2AX foci per nucleus was analyzed by immunohistochemistry 2h after doxorubicin treatment. Microscopic
images displayed are representative. The histogram shows the mean±S.D. from three independent experiments. *Pr0.05, signiﬁcantly different from Doxo-treated cells.
(c) Formation of DSBs was analyzed by the neutral comet assay 2h after treatment. For control, cells were irradiated with 10Gy (IR). Shown is the increase in tail DNA as
comparedwithuntreatedcontrol.Thehistogramshowsthemean±S.D.obtainedfromﬁveindependentexperiments.*Pr0.05,signiﬁcantlydifferentfromDoxo-treatedcells.
(d) The level of DNA strand breaks was analyzed by the alkaline comet assay. For control, cells were irradiated with 5.5Gy (IR). The histogram shows the mean±S.D. from
three independent experiments. ns, difference from Doxo-treated cells is statistically not signiﬁcant. (e) The expression of Topo IIa and Topo IIb protein was analyzed by
western blot. ERK2 protein expression was determined as internal loading control. Con, untreated control (f) 1h and 2h after doxorubicin treatment, the protein level of
topoisomerases was analyzed by western blot
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Cell Death and Diseaseof farnesyltransferase (Figure 4a). Furthermore, speciﬁc
inactivation of the Rho GTPase Rac1 by the clostridial
toxins TcsL and TcdBF
39,40 also attenuated doxorubicin-
induced H2AX phosphorylation (Figure 4a). In addition, the
Rac1 inhibitor NSC23766 also mitigated doxorubicin-
triggered phosphorylation of H2AX (Figure 4b). Apparently,
Rac1 is essential for this genotoxic stress response provoked
by doxorubicin. Rac1-mediated signaling to H2AX partially
depends on the activity of stress-activated protein kinases
(SAPK/JNK), as pharmacological inhibition of this kinases
reduced doxorubicin-induced H2AX phosphorylation
(Figure 4c). Inhibition of p38 kinase increased the basal
level of phosphorylated H2AX by its own (Figure 4c).
Doxorubicin exposure in the presence of p38 kinase
inhibitor (p38i) further increased the level of phosphorylated
H2AX, although this increase was lower than observed in
the absence of p38i (Figure 4c). Collectively, Rac1-regulated
and SAKP/JNK-related signaling impact gH2AX phosphory-
lation following doxorubicin treatment.
Doxorubicin-induced acute and subacute heart damage
are reduced by lovastatin. On the basis of our in vitro
ﬁndings, we hypothesized that lovastatin may reduce
cardiotoxicity, which is the major dose-limiting side effect of
doxorubicin in cancer patients. To scrutinize this hypothesis,
Balb/c mice, either untreated or pre-treated with lovastatin
were exposed to a single dose of doxorubicin and acute
heart damage was analyzed 48h later by measuring the
mRNA levels of pro-inﬂammatory and pro-ﬁbrotic
cytokines. We observed that the mRNA expression of the
pro-ﬁbrotic connective tissue growth factor (CTGF) was
clearly enhanced by doxorubicin. Lovastatin blocked this
doxorubicin-stimulated pro-ﬁbrotic acute stress response
(Figure 5a). In the liver, which was included as a control,
doxorubicin stimulated the expression of both pro-
inﬂammatory and pro-ﬁbrotic cytokines and lovastatin
blocked both types of stress responses (Figure 5b).
In the clinic, the frequency and severity of congestive heart
failure depends on the cumulative anthracycline dose and
oftenoccursasadelayedeffect.Tomimictheclinicalsituation
in humans, Balb/c mice were repeatedly treated with
doxorubicin (3 3mg/kg; i.p.) and subacute toxicity was
monitored 21 days after the ﬁrst doxorubicin administration.
Lovastatin (10mg/kg; p.o.) was administered 3–4 times a
week. Doxorubicin caused loss in body weight of about 20%,
which was not affected by lovastatin (see Supplementary
Figure S2). The heart weight/body weight ratio was
not signiﬁcantly changed under these conditions (data not
shown). Doxorubicin increased the mRNA levels of CTGF in
the heart, which was largely impaired by the statin (Figure 5c).
Figure 3 Lovastatin-mediated inhibition of doxorubicin-induced H2AX phosphorylation is independent of ROS. (a and b) H9c2 cells were treated with lovastatin (20mM;
overnight). Afterwards, cells were loaded with DCFDA (1mM; 30min) before a doxorubicin pulse (1mM, 1h) was applied. Intracellular ROS formation was monitored by
microscopy (a) or FACS analysis (b). H2O2 was used as positive control. (c) H9c2 cells were pre-treated with the antioxidants curcumin (Cuc; 12.5mM), resveratrol (Res;
10mM) or N-acetylcysteine (NAc; 10mM) for 1h. Afterwards, doxorubicin (1mM) was added and phosphorylation of H2AX was analyzed 1h later by western blot. The
histogram shows the mean±S.D. obtained from the densitometrical quantitation of three independent experiments. Relative gH2AX level in untreated cells (Con) was set to
1.0. The differences observed in the presence of the antioxidants were not signiﬁcantly different from the doxorubicin only treated cells. (d and e) H9c2 cells were exposed to
etoposide(7.5mM)(d)orwereirradiatedwith5Gy(IR)(e)andH2AXphosphorylationwasmonitored1hlaterbywesternblot.Quantitativedata(mean±S.D.)shownunderd
result from three independent experiments. *Pr0.05, statistically signiﬁcant difference from Eto control
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Cell Death and DiseaseLovastatin also mitigated the doxorubicin-provoked large
increase in the amount of atrial natriuretic peptide (ANP)
mRNA, as well as the concomitant downregulation of alpha
skeletal muscle actin (acta1) mRNA expression (Figure 5d).
mRNA level of the brain natriuretic peptide (BNP) was not
altered under our experimental conditions (Figure 5d).
Figure 4 Rac1 in involved in doxorubicin-stimulated DDR. (a) H9c2 cells were pre-treated with lovastatin (Lova) (20mM), geranylgeranyl transferase inhibitor (GGTI)
(20mM) or farnesyl transferase inhibitor (FTI) (2mM) for 16h. Pre-treatment with Clostridium difﬁcile toxin BF (TcdBF) (1mg/ml) or Clostridium sordellii lethal toxin (TcsL)
(10mg/ml) was carried out for 2h. Afterwards, doxorubicin (1mM) was added and H2AX phosphorylation (gH2AX) was analyzed 1h later by western blot. The histogram
shows quantitative data (mean±S.D.) which were obtained from three independent experiments. Relative gH2AX level in untreated cells (Con) was set to 1.0. *Pr0.05,
signiﬁcantlydifferentfromDoxo-treatedcells.(b)H9c2cellswerepre-treatedwiththeRac1-GEFinhibitorNSC23766(100mM,3h)beforedoxorubicinexposure(1mM).H2AX
phosphorylation was assayed 1h later. (c) After 1h pre-treatment with p38 kinase inhibitor SB203580 (p38i) (10mM) or JNK inhibitor (JNKi) (10mM), doxorubicin (1mM) was
added.Afterfurtherincubationperiodof1h,phosphorlyationofH2AXwasanalyzedbywesternblot.Thehistogramshowsquantitativedata(mean±S.D.)obtainedfromfour
independent experiments. Relative gH2AX level in untreated cells (Con) was set to 1.0. *Pr0.05, signiﬁcantly different from Doxo-treated cells
Figure 5 Lovastatin attenuates acute and subacute toxic effects of doxorubicin in vivo.( a and b) Balb/c mice were left untreated or were pre-treated twice with lovastatin
(Lova) (10mg/kg; p.o.). At 48h after exposure to a single dose of doxorubicin (Doxo) (10mg/kg; i.p.) mice were killed and the mRNA expression of pro-inﬂammatory (TNFa,
IL-6) and pro-ﬁbrotic (CTGF) genes was analyzed by real-time PCR in heart (a) and liver (b). Relative mRNA expression in the control was set to 1.0. (c) Balb/c mice were
repeatedly exposed to doxorubicin (3 3mg/kg; i.p.). Lovastatin was applied on a regular basis as described in methods. Mice were killed 21 days after the ﬁrst doxorubicin
administration. The mRNA expression of CTGF was analyzed in heart and set to 1.0 in untreated control. The gel picture shows the result of a semiquantitative RT-PCR
analysis. The data shown in the histogram are abtained from quantitative real-time RT-PCR analyses as described in methods. (d) Balb/c mice were treated with doxorubicin
and lovastatin as described under (c). Cardiac mRNA levels of ANP, BNP and Acta1 (d) were analyzed by quantitative real-time RT-PCR analysis using b-actin and GAPDH
mRNAlevelsasinternalcontrols.RelativemRNAlevelsinuntreatedcontrolswassetto1.0.(e)Cardiotoxicitywasdeterminedbyanalyzingtheserumconcentrationofcardiac
troponin I using ELISA-based method at day 9 and 16. Nd, not detectable. (f) Balb/c mice were treated with doxorubicin and lovastatin as described under C. Cardiac tissue
sections were analyzed with regard to ﬁbrosis using the Masson’s trichrome staining protocol. Fibrotic tissue is stained in cyan color. Shown are representative pictures
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Cell Death and DiseaseFurthermore, lovastatin reduced the doxorubicin-stimulated
increase in the serum level of cardiac troponin I (Figure 5e),
showing that lovastatin counteracts subacute cardiotoxicity
evoked by doxorubicin in vivo. This gains support by the
ﬁnding that the onset of cardiac ﬁbrosis, which was monitored
by collagen staining (that is, Masson’s trichrome staining)
of cardiac tissue sections, was constrained by the statin
(Figure 5f). Lovastatin did not show major effects on
doxorubicin-stimulated acute changes in the expression of
genes coding for antioxidative proteins or drug transporter
(Supplementary Figure S3). Under situation of subacute
doxorubicin exposure, lovastatin slightly mitigated the doxor-
ubicin-induced increase in the amount of heme oxygenase-1
(ho-1) mRNA (Supplementary Figure S3). In addition,
lovastatin lowered the doxorubicin-induced decrease in the
number of peripheral leukocytes (data not shown). Collec-
tively, a protective effect of lovastatin against the deleterious
effects of anthracyclines was observed not only in vitro in
H9c2 cardiomyoblasts, but also in vivo using a mouse model
and therapeutically relevant doses.
Lovastatin affects doxorubicin-induced alterations in
the gene expression of resistance-related factors.
Genotoxic stress is known to provoke complex changes in
gene expression, including players involved in DNA repair,
checkpoint control and cell death that are major determinants
of cellular sensitivity/resistance. Therefore, we examined the
impact of lovastatin on doxorubicin-induced alterations in gene
expression in the heart using the described subacute in vivo
model. mRNA expression levels were analyzed by means of
quantitative real-time RT-PCR making use of a semi-
customised PCR array, which enables the analysis of the
mRNA expression of 94 genes coding for major proteins
involved in DNA repair, DNA damage response, checkpoint
control and cell death. The screening analyses revealed quite
complex changes in gene expression (see Supplementary
Figure S4). Genes exhibiting considerable changes in their
expression were selected for further validation by real-time
RT-PCR analysis. As shown in Figure 6, doxorubicin caused
upregulation of cell-cycle regulatory genes (cdc25A, wee1), as
well as some DNA repair-associated genes (ddb2, rev1,
brca2) and heme oxygenase-1 (ho-1). By contrast, the
mRNA level of topo IIa was reduced following doxorubicin
treatment (Figure 6). Lovastatin mitigated each of these stress
responses. Some of the induced genes, such as ddb2,a r e
induced by DNA damage.
41,42 Thus, these data strongly
indicate that lovastatin suppresses DNA damage formation
and downstream responses in the heart.
Lovastatin potentiates the antitumor activity of
doxorubicin in vivo. From these data it is reasonable to
conclude that lovastatin might reduce the patient’s risk for
heart failure following doxorubicin-based cancer therapy.
However, does under these conditions the statin also
mitigates the anticancer efﬁcacy of doxorubicin? To
address this concern, we examined the effect of lovastatin
on doxorubicin-induced cell killing of human ﬁbrosarcoma
cells (HT-1080). Fibrosarcoma cells were chosen as the
regimen for their treatment contains anthracyclines as ﬁrst-
line therapeutics. These data revealed that lovastatin did not
protect HT-1080 cells against doxorubicin in vitro (Figures 7a
and b). Rather, the statin provoked a weak sensitizing effect.
Also, the doxorubicin-stimulated phosphorylation of H2AX
was not reduced by lovastatin in HT-1080 cells (Figure 7c).
To substantiate these data, we investigated the antitumor
effect of doxorubicin and lovastatin on the growth of HT-1080
cells in vivo using a xenograft mouse model. Monotherapy
with lovastatin caused only a very weak retardation, whereas
administration of doxorubicin clearly reduced tumor growth
(Figure 7d). Animals that received both doxorubicin and
lovastatin showed a slower increase in tumor size as
compared with untreated, lovastatin-treated or doxorubicin-
treated individuals (Figure 7d). Taken together, co-treatment
with lovastatin potentiates the antitumor efﬁcacy of
doxorubicin in a human ﬁbrosarcoma xenograft model
in vivo.
Discussion
Unwanted effects of anticancer drugs severely impact the
prognosis and life quality of cancer patients. Therefore, the
developmentofnovelprotectivestrategiespreventingnormal-
tissue damage caused by anticancer drugs is of high clinical
importance. Anthracycline derivatives such as doxorubicin
are potent therapeutics. However, they provoke considerable
acute and delayed normal tissue damage, in particular of the
heart. Previously, we reported that the HMG-CoA reductase
inhibitor lovastatin protects primary human endothelial
cells from the deleterious effects of ionizing radiation and
doxorubicin in vitro.
27,28 As cardiotoxicity is the clinically most
relevant side effect of anthracyclines, we extended our in vitro
studies to cardiomyoblasts. As shown here, lovastatin
protects rat cardiomyoblasts from doxorubicin-induced cell
death. This was related to attenuated DNA damage induction,
as shown by a reduced Ser139 phosphorylation of histone
Figure 6 Lovastatin affects doxorubicin-induced changes in the mRNA
expression of drug resistance-related factors.Balb/c mice were repeatedlyexposed
to doxorubicin (3 3mg/kg; i.p.). Lovastatin was applied on a regular basis as
described in methods. Mice were killed 21 days after the ﬁrst doxorubicin
administration. The mRNA level of genes involved in DNA repair, DNA damage
response, cell-cycle progression and cell death was analyzed in heart using a semi-
customized quantitative RT-PCR-array as described in methods. The results
obtained (see Supplementary Figure S4) were conﬁrmed by quantitative real-time
RT-PCR for a subset of selected genes as depicted. The relative mRNA amount in
untreated animals was set to 1.0 (dashed line). Changes in mRNA levels of Z0.5
r 2-fold (horizontal lines) were considered as not relevant
Statins mitigate doxorubicin-induced cardiac damage
J Huelsenbeck et al
6
Cell Death and DiseaseH2AX, which is a generally accepted marker of the presence
of DNA breaks.
34,35,43 The geno-protective effect of lovastatin
is independent of changes in doxorubicin transport and,
furthermore, is not related to ROS, which are often discussed
to trigger adverse effects of anthracyclines.
44 Rather, it
appears to rest upon a reduced inhibition of topo II by
doxorubicin, resulting in mitigation of DNA damage formation.
Hence, it is tempting to speculate that lovastatin interferes
with either the formation or the processing to topo II cleavable
complexes. Apparently, the low molecular weight GTPase
Rac1 is essential for H2AX phosphorylation following doxor-
ubicin exposure. This is consistent with the notion that Rho
GTPases, in particular Rac1, are highly relevant targets of
statins.
19,45,46 These data are indicative of a so far not
recognized crosstalk between Rho GTPases and genotoxic
stress responses following the inhibition of topo II. The recent
ﬁnding of a nuclear localization of Rac1
47 and Rho-activating
GEFs
48 support this hypothesis.
The usefulness of lovastatin as a cardioprotective drug was
conﬁrmed by measuring the acute and subacute toxicity of
doxorubicinusinganinvivomodelsystem.Ourdatashowthat
oral administration of lovastatin to Balb/c mice largely
attenuated the acute pro–ﬁbrotic stress response of cardio-
myocytes (for example, the mRNA level of CTGF), which was
observed 48h after doxorubicin administration. A similar
protective effect of lovastatin was found upon exposure of
Balb/c mice to three consecutive doxorubicin doses and
assaying subacute toxicity 8 days after the last doxorubicin
treatment. Here, the mRNA amount of pro-ﬁbrotic CTGF and
of ANP, but not of BNP, were increased in response to
doxorubicin while the the level of acta1 mRNA was reduced.
Lovastatin was able to block these doxorubicin-stimulated
alterations. Furthermore, lovastatin also alleviated cardiotoxi-
cityasdeterminedbytheanalysisoftheserumconcentrations
of troponin I and by monitoring cardiac ﬁbrosis in tissue
sections. Changes in heart weight/body weight ratio were not
observed after doxorubicin administration (data not shown).
This might be due to the rather short postincubation times.
The effect of doxorubicin and statins on chronic cardiac
damage is subject of ongoing studies.
These data reported here show that lovastatin has a clear
protective effect against doxorubicin-provoked heart damage.
Regarding the mechanism possibly involved, we found
that lovastatin mitigates doxorubicin-induced alterations in
the gene expression of resistance-related factors, including
the DNA repair protein DDB2 and cell-cycle regulatory
phosphatases (that is, CDC25A, Wee1). As ddb2 is a DNA
damage inducible gene,
41,42 these data indicate that lovasta-
tin lowers the level of doxorubicin-induced cardiac DNA
damage. This assumption is in line with our in vitro results
obtained with cardiomyoblasts. Yet, we have to admit that,
under our experimental conditions, we failed so far to detect
Figure7 Effectoflovastatinondoxorubicin-inducedresponsesofﬁbrosarcomacells.HumanHT-1080ﬁbrosarcomacellswereleftuntreated( Lova)orwerepre-treated
with lovastatin (þLova) (1mM, overnight) before pulse treatment (1h) with doxorubicin. (a and b) After incubation period of 72h, cell viability was monitored (a). Relative cell
viability in untreated cells was set to 100%. The percentage of apoptotic cells was analyzed by FACS-based determination of Annexin V positive cells (b). Results presented
are the mean±S.D. from ﬁve independent experiments. (c) H2AX phosphorylation (gH2AX) was assayed 1h after doxorubicin treatment by western blot (upper panel) or
immunohistochemistry(lower panel). Doxo1 (0.2mM); Doxo2 (0.3mM) Doxo3 (1.0mM). (d) For the xenograft study, HT-1080 ﬁbrosarcoma cells were injected into both ﬂanks
of immunodeﬁcient mice. After 5 days, lovastatin treatment started. Doxorubicin treatment was performed as described before. Tumor sizes were determined three times a
week in each animal (number of tumors analyzed: Con, n¼6; Lova, n¼8; Doxo, n¼6; Doxo þLova, n¼9). The lower part of the ﬁgure illustrates the tumor size 15 days
after the onset of doxorubicin and/or lovastatin treatment
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acute model system (that is, 48h after administration of a
single doxorubicin dose of 10mg/kg), we could not detect
an increase in cardiac H2AX phosphorylation, neither by
immunohistochemistrynorbywesternblotanalysis.Alsoafter
a shorter period of time (that is, 6h after doxorubicin
administration) western blot analysis failed to detect a
signiﬁcant change in gH2AX. Apparently, the degree of
cardiac DNA damage induced in our experimental setting is
quitelow and,hence,difﬁculttodetect.Inthiscontextitshould
be noted that in liver, which was included for reasons of
control, doxorubicin was able to stimulate phosphorylation of
H2AX (data not shown). As the statin also reduced
the doxorubicin-induced drop in peripheral leukocyte count
(data not shown) and alleviated acute hepatotoxicity, it
appears possible that lovastatin counteracts multiple adverse
pathways of anthracyclines in vivo. This hypothesis, which is
currently under further investigation, gains support by
previous reports showing that statins also reduce normal
tissue damage, in particular of the intestine, following radio-
therapy.
29–31,49 Moreover, statins are well known to protect
the myocardium from acute ischemia-reperfusion injury
32 and
to alleviate aminoglycoside-induced nephrotoxicity.
50 Collec-
tively, our data together with published reports support the
hypothesisofpleiotropicorganoprotectivefunctionsofstatins.
Most important, we found that, while protecting cardiac tissue,
lovastatin potentiated the killing efﬁcacy of doxorubicin
on cancer cells (that is, human ﬁbrosarcoma cells) in vivo.
This ﬁnding is in line with reports demonstrating an additive or
synergistic effect of statins on anticancer drug- and radiation-
induced tumor cell kill in vitro.
19,20
Overall, our in vitro and in vivo data provide evidence that
lovastatin, which is a widely used lipid-lowering drug, protects
heart cells against the acute and delayed side effects of the
anthracycline derivative doxorubicin. At the same time, the
statinpromotestumorcelldeathfollowingdoxorubicintreatment
in vivo. The geno-protective effect of lovastatin on cardiomyo-
cytes appears to be due to inhibition of Rac1-regulated
functions and, furthermore, is related to the inhibition of topo II
rather than ROS formation. In consequence, pro-ﬁbrotic
signaling mechanisms and cell death provoked by doxorubicin
arereducedbylovastatin.Basedonthesedata,wesuggestthat
including lovastatin into current anthracycline-based tumor-
therapeutic protocols will widen the therapeutic window of
anthracyclines by reducing cardiac damage and, at the same
time, amending the tumor-cell response.
Materials and Methods
Materials. The following antibodies have been used: gH2AX anti-mouse
antibody (pS139) (Millipore, Billerica, MA, USA), gH2AX anti-rabbit antibody
(pS139)(Epitomics,Burlingame,CA,USA),ERK2(SantaCruz,CA,USA),TopoIIa
(Enzo Life Sciences, Lo ¨rrach, Germany), Topo IIb antibody (Abcam, Cambridge,
MA, USA), p-Chk1 (Ser 345), Chk1 (Cell Signaling Technology, Inc., Beverly,
MA, USA), peroxidise-conjugated secondary antibodies (Rockland, Gilbertsville,
PA, USA) and Alexa Fluor 488 labeled secondary antibodies from Invitrogen
(Paisley, UK). Alexa Fluor 488-conjugated Annexin V was from Axxora (Lo ¨rrach,
Germany), WST-1 from Roche (Mannheim, Germany). Prenyltransferase inhibitor
GGTI-286 and FTI-2148, the Rac1 inhibitor NSC23766, JNK inhibitor type II and
p38 kinase inhibitor SB203580 were from Calbiochem (San Diego, CA, USA).
RNeasy Mini Kit for total mRNA preparation and OmniScript Kit for cDNA synthesis
were from Qiagen (Hilden, Germany), DNA oligos from SIGMA-Aldrich (Steinheim,
Germany). The Mouse Cardiac Troponin I ELISA Kit was provided by Life
Diagnostics(West Chester,PA, USA). Rhoinactivatingclostridialtoxins Clostridium
difﬁcile toxin BF and Clostridium sordellii lethal toxin were generously provided by I
Just and H Genth (Hannover, Germany).
Cell culture. H9c2 rat cardiomyoblasts were grown at 371C in DMEM
supplemented with 20% fetal calf serum and penicillin/streptomycin. HT1080 cells
were grown in RPMI supplemented with 5% fetal calf serum and penicillin/
streptomycin.
Determination of viability and apoptotic cell death. Cell viability was
monitoredbyuseoftheWSTassayaccordingtothemanufacturersprotocol(Roche
Diagnostics, Mannheim, Germany). Apoptotic cell death was determined by
analysing the fraction of FITC-Annexin V positive cells by FACS (Becton Dickinson,
Heidelberg, Germany). Values given are the mean±S.E.M. of four to ﬁve
independent experiments.
Cell-cycleanalysis. At 24h after treatment as indicated,cells were harvested
and ﬁxed in an ice-cold 70% ethanol. After RNase treatment (1h, RT), DNA was
stained by propidium iodide. Cell-cycle distribution was analyzed by FACS. Data
shown are mean values from three independent experiments.
Western blot analysis. Total cell extracts were prepared by lysing identical
number of cells (about 2–5 10
5) in Roti-load (Roth, Karlsruhe, Germany) sample
buffer. Proteins were separated by SDS-PAGE (10–15% gels) and transferred onto
nitrocellulose membranes. Membranes we r et h e nb l o c k e di n5 %n o n - f a tm i l ki nT B S /
0.1%Tween20for Z1h atroom temperature.Incubation with theprimary antibody (as
indicated) wasconductedovernightat41C.Incubationwithperoxidase-conjugatedanti-
mouse or anti-rabbit secondary antibody (1:2000) (Rockland) was performed for 2h at
room temperature. Bound antibodies were then visualized by chemiluminescence and
Hyperﬁlm ECL (GE Healthcare, Munich, Germany). Densitometrical quantiﬁcation was
performed with the Multi Analyst software (BioRad, Munich, Germany). Quantitative
datafrominvitroexperiments arebasedonthreeindependentexperiments,invivodata
are calculated from the analysis of ﬁve to six mice.
Immunhistochemical analysis of H2AX phosphorylation. Cells
were seeded onto cover slides. After treatment, cells were ﬁxed with 4%
paraformaldehyde (15min, RT), followed by incubation with ice-cold methanol
( 201C, 1h). After blocking (PBS containing 0.1% TWEEN-20/1% BSA (w/v), 2h,
RT) incubation with an antibody speciﬁc for phosphorylated (Ser139), histone H2AX
(1:500) was conducted overnight at 41C. Incubation with the secondary ﬂuorescent-
labeled antibody (Alexa Fluor 488; Invitrogen) was performed for 2h at room
temperature in the dark. For microscopical analysis a Zeiss Axiovert 35 (Carl Zeiss
AG, Oberkochen, Germany) was used. Values given are the mean±S.D. from three
independent experiments with 50 cells each being analyzed.
Analysis of DNA strand break induction. Formation of DNA strand
breaks was assayed by the comet assay.
51 Comets were visualized by microscopy
and quantiﬁed by determination of the percentage of DNA in the tail (Komet 4.02,
Kinetics Imaging, Merseyside, UK). A total of 50 nuclei were evaluated per
treatment. The mean±S.D. from at least three independent experiments is shown.
Determination of doxorubicin transport (uptake and efﬂux). To
this end, doxorubicin-treated cells were ﬁxed in an ice-cold 70% ethanol ( 201C,
1h) and analyzed by FACS (Becton Dickinson). The inherent ﬂuorescence
of doxorubicin (exc.: 470nm; emm.: 575nm) was taken as indication of the
doxorubicin content of the cells. To measure doxorubicin uptake, cells were treated
with doxorubicin for 1h before FACS analysis was performed. To determine
doxorubicin efﬂux, cells were pre-loaded with doxorubicin (1h pulse treatment),
followedby postincubation periodof 6h intheabsenceof thedrug.The decrease in
ﬂuorescence occurring within this period of time is taken as indication of drug efﬂux.
A representative histogram out of three independent experiments is shown.
In vivo experiments. Balb/c mice were 3–4 months of age and weighed an
average of 20–25g at the start of the experiments. In all, 24 (or 32 in case of the
xenograftstudy)animalswererandomlydividedintogroupsofsixanimalspergroup
(or eight animals per group in case of the xenograft study). To determine the effect
of lovastatin on acute toxicity of doxorubicin, mice were pre-treated twice with
lovastatin(10mg/kg;p.o.).At2daysafterdoxorubicinadministration(10mg/kg;i.p.)
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weretreatedwithlovastatin3–4timesperweek(10mg/kg;p.o.).Threesingledoses
of doxorubicin (3mg/kg; i.p.) were applied on days 3, 9 and 16. At 8 days after the
last doxorubicin injection, mice were killed. Body and heart weight was determined
for the calculation of heart weight/body weight ratio. Organs were immediately
frozen in liquid nitrogen and stored at  801C or were ﬁxed in formalin and
embeddedinparafﬁnforhistologicalanalysis.Bloodsampleswerecollectedatdays
9 and 16 from the tail vein and at the end of the experiment from tail vein and heart.
For the xenograft study, 4 10
6 HT1080 cells were injected subcutaneously into
each ﬂank of immunodeﬁcient Rag2
 /  mice. Tumors growing during the ﬁrst
week of the treatment were included in the ﬁnal evaluation. Data shown are the
mean±S.E.M.
Analysis of gene expression by PCR array. Balb/c mice were treated
with doxorubicin (3 3mg/kg, i.p) and lovastatin (3 10mg/kg per week, p.o.) as
described before. At 3 weeks after the ﬁrst doxorubicin administration, the effect of
lovastatin on doxorubicin-induced alterations in mRNA expression levels was
analyzed.To thisend,totalRNAwasisolatedfromheartforreal-timePCRanalysis.
Real-time PCR analysis was performed using pooled mRNA samples from n¼6
mice. The PCR array used in this study was semicustomised (established
in collaboration with Sigma-Aldrich Chemie GmbH, Steinheim, Germany).
It contains 94 genes involved in DNA repair, stress signaling, cell-cycle regulation
and metastasis. Ampliﬁcation was performed using the MyIQ real-time PCR cycler
(BioRad). At the end of the run, melting curves were analyzed to ensure the
speciﬁcity of the ampliﬁcation reaction. PCR products with crossing points of Z35
cycles were omitted. mRNA expression levels were normalized to that of the
housekeeping genes GAPDH and b-actin. Relative gene expression in untreated
control animals was set to 1.0 and compared with that of lovastatin-treated animals.
Only changes in gene expression of r0.5 and Z2-fold were considered as
relevant. Selected genes that responded to doxorubicin or lovastatin treatment
with relevant changes in mRNA expression were validated by performing additional
real-time RT-PCR analyses (triplicate determinations).
Gene expression analyses (real-time RT-PCR). Total RNA was
puriﬁed from 20–30mg of tissue using the RNeasy Mini Kit (Qiagen). The RT
reaction was performed using the OmniScript Kit (Qiagen) using 500–2000ng of
mRNA. For each PCR reaction, 2ml of diluted (1:10) cDNA, primers (0.42mM
each), and dNTPs (0.35mM each; Perkin Elmer, Waltham, MA, USA) were used.
PCR runs were carried out as follows: 1. 951C, 2min; 2. 951C, 30s–601C,
30s–721C, 40s; 3. 721C, 10min. For semiquantitative end-point analysis, PCR products
were separated on agarose gels and stained with ethidium bromide. Real-time
RT-PCRanalysiswasperformedwithpooledRNAsamplesfromuptosixmiceandwas
carried out in duplicates using the QPCR SYBR Green Fluorescein Mix (Thermo
Fisher, Dreieich, Germany) and a MyIQ Thermal Cycler (BioRad). The following
primers were used: GAPDH, f: 50-AACTTTGGCATTGTGGAAGG-30,r :5 0-CACA
TTGGGGGTAGGAACAC-30 (222bp product); b-actin, f: 50-GCATTGCTGACA
GGATGCAG-30,r :5 0-CCTGCTTGCTGATCCACATC-30 (159bp); connective tissue
growth factor (CTGF), f: 50-CAAAGCAGCTGCAAATACCA-30,r :5 0-GGCCAA
ATGTGTCTTCCAGT-30 (220bp); interleukin-6 (IL-6), f: 50-AGTTGCCTTC
TTGGGACTGA-30,r :5 0-CAGAATTGCCATTGCACAAC-30 (191bp); tumor
necrosis factor alpha (TNFa,f :5 0-AGCCCCCAGTCTGTATCCTT-30,r :5 0-CTC
CCTTTGCAGAACTCAGG-30 (212bp); heme oxygenase (ho-1); f: 50-CACGCA
TATACCCGCTACCT-30 r: 50-CCAGAGTGTTCATTCGAGCA-30; glutathione
peroxidase (gpx-1), f: 50-GTCCACCGTGTATGCCTTCT-30 r: 50-GAACTGATTGC
ACGGGAAAC-30; multidrug resistance gene 1 (mdr-1), f: 50-ACCATGGA
GGAAATCACAGC-30 r: 50-TGGTGGCATCATCCAAGATA-30; multidrug
resistance-associated protein 1 (mrp-1): f: 50-AGGCCTACTACCCCAGCATT-30 r:
50-CAGTCTCTCCACTGCCACAA-30; atrial natriuretic peptide (ANP): f: 50-CCT
AAGCCCTTGTGGTGTGT-30 r: 50-CAGAGTGGGAGAGGCAAGAC-30; brain
natriuretic peptide (BNP): f: 50-CTGAAGGTGCTGTCCCAGAT-30 r: 50-CC
TTGGTCCTTCAAGAGCTG-30; alpha sceletal muscle actin (acta1): f: 50-GCG
CAAGTACTCAGTGTGGA-30 r: 50-TCGTCCTGAGGAGAGAGAGC-30. mRNA
levels of GAPDH and b-actin were taken for normalization.
Determination of troponin I serum level and white blood cell
count. Serum troponin I levels were detected using the Mouse Cardiac Tn-I
ELISA (Life Diagnostics, West Chester, PA, USA). Values given are the
meanþS.D. from at least three animals per group. White blood cell count was
determined by routine analysis in the Institute of Clinical Chemistry and Laboratory
Medicine (Universita ¨tsmedizin Mainz, Germany). Data shown are based on the
analysis of four to six animals per group.
Fibrosis staining. To detect ﬁbrosis in cardiac tissue histologically, heart
tissue was ﬁxed with formalin and embedded into parafﬁn blocks by routine
procedure (Institute of Pathology, Mainz). Three sections per heart were prepared
for ﬁbrosis staining using the Masson-Goldner trichrome staining kit (MERCK
Darmstadt, Germany). Four animals per group were analyzed. Photographs were
taken on a Zeiss Axiovert 35 microscope and representative pictures are shown.
Statistical analysis. For statistical analysis the Student’s t-test or the
Mann–Whitney U-test were applied. P–values of Pr0.05 were considered
signiﬁcant and marked with an asterisk.
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